Close Menu
  • Home
  • Technology
  • Devices
  • Business
  • Science
  • Gadgets
  • Startups
Ayaksız
  • Home
  • Technology

    Lucid and Bolt Plan 25,000 Robotaxis for Europe

    Eylül 18, 2026

    AMD Gives PC Builders More Choice With New Ryzen 5 Desktop Chips

    Eylül 11, 2026

    Apple Expands Device Protection With a $49.99 Family Plan

    Eylül 11, 2026

    Snapdragon 8 Elite Extreme Gen 6 Reportedly Beats MediaTek’s Next Flagship Chipset

    Eylül 11, 2026

    Pinterest CFO Julia Donnelly to Step Down in October

    Ağustos 30, 2026
  • Devices

    Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone

    Kasım 18, 2026

    Router Mode or Access Point Mode? Give Each Network Device a Clear Job

    Kasım 18, 2026

    Scanner Feeder or Glass? Choose According to the Original

    Kasım 13, 2026

    Borderless Printing: Why the Edges of Your Photo Can Disappear

    Kasım 12, 2026

    Camera AE Lock: Recompose a Scene Without Letting Exposure Drift

    Kasım 11, 2026
  • Business

    Google Pixel 11 Pro Leaked Renders Indicate It Might Sport Thinner Bezels Than the Pixel 10 Pro

    Mart 30, 2026

    Motorola Edge 70 Debuts With Snapdragon 7 Gen 4, Ultra-Slim 5.99mm Body

    Kasım 5, 2025

    Samsung Galaxy S26 Series Could See Price Increase Amid Rising Component Costs: Report

    Kasım 4, 2025

    Amazon’s AWS Partners with NBA to Power New AI Basketball Platform

    Ekim 4, 2025

    Billionaire-Backed Bitcoin Firm OranjeBTC to List on Brazil’s B3 Exchange

    Ekim 4, 2025
  • Science

    Double Rainbows: Why the Outer Arc Reverses Its Colors

    Kasım 18, 2026

    Why Ice Floats—and Why Water Behaves Differently Near Freezing

    Kasım 13, 2026

    Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

    Kasım 12, 2026

    A Light-Year Measures Distance: Understanding the Scale Behind Space Headlines

    Kasım 11, 2026

    Why the Sky Is Blue—and Why the Same Atmosphere Produces Red Sunsets

    Kasım 10, 2026
  • Gadgets

    Tripod Center Columns: Extra Height Comes with a Stability Tradeoff

    Kasım 18, 2026

    E Ink Ghosting: Match the Refresh Mode to the Task

    Kasım 13, 2026

    Camera Lens Hoods: Choose the Right Shape and Check the Whole Frame

    Kasım 12, 2026

    Pop Filters and Windscreens: Match Microphone Protection to the Noise

    Kasım 12, 2026

    USB Hub Power: Check Where Your Connected Devices Get Their Energy

    Kasım 11, 2026
  • Startups

    Cache-Control for Startups: No-Cache and No-Store Solve Different Problems

    Kasım 18, 2026

    Dead-Letter Queues: Investigate Before Replaying Failed Messages

    Kasım 13, 2026

    Database Connection Pools: Budget Across Every Application Replica

    Kasım 13, 2026

    Startup Staging Sites: Separate Search Visibility from Access Control

    Kasım 12, 2026

    API Idempotency Keys: Keep a Retry Connected to the Original Operation

    Kasım 11, 2026
Ayaksız
Anasayfa » Blog » Long-term Benefits of Alzheimer’s Drug Leqembi Demonstrated in New Study
Science

Long-term Benefits of Alzheimer’s Drug Leqembi Demonstrated in New Study

By ayaksızAğustos 5, 2024Yorum yapılmamış3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

The Alzheimer’s drug Leqembi has shown promising long-term benefits in slowing disease progression, according to new data released by Eisai, a Japanese drugmaker. The study, presented at the Alzheimer’s Association International Conference, highlights the importance of continued treatment for sustained cognitive and functional benefits.

Key Findings from the Study

  1. Disease Progression Slowed Over Three Years:
    • Patients on Leqembi experienced a slower progression of Alzheimer’s disease over three years.
    • Stopping treatment led to a worsening of the disease, reinforcing the need for ongoing therapy.
  2. Reduced Adverse Side Effects:
    • Side effects such as brain bleeding and swelling decreased after six months of treatment, addressing major concerns that have hindered the drug’s approval in Europe.
  3. Efficacy and Safety Data:
    • This study provides the longest available efficacy and safety data on Leqembi, adding to the 24-month data released previously.
  4. Mechanism of Action:
    • Leqembi is a monoclonal antibody targeting amyloid plaques in the brain, a hallmark of Alzheimer’s disease. It also clears protofibrils, the building blocks of amyloid plaque.
  5. Importance of Early and Sustained Treatment:
    • Early and continuous treatment with Leqembi is crucial for maintaining cognitive function and slowing disease progression.
  6. Potential for Maintenance Dose:
    • Eisai suggests that patients may eventually switch to a maintenance dose after 18-24 months of initial treatment, possibly reducing the frequency of infusions.
  7. Regulatory Approval for New Administration Methods:
    • Eisai and Biogen are seeking approval for a once-monthly infusion of Leqembi and an injectable form that can be administered at home, potentially improving patient convenience and adherence.

Detailed Study Insights

  • Phase Three Trial (Clarity AD):
    • Examined three groups: continuous Leqembi treatment for three years, a placebo group for 18 months followed by Leqembi, and a group with no treatment.
    • The continuous treatment group showed the slowest cognitive decline.
    • Those who switched from placebo to Leqembi also benefited, but their disease progression was worse compared to those who started Leqembi earlier.
  • Sub-study on Tau Protein:
    • Patients with low levels of tau protein (indicative of early-stage Alzheimer’s) showed significant benefits.
    • 59% of these patients did not see their disease progress after three years, and over half saw an improvement.
  • Phase Two Trial (Study 201):
    • Patients who stopped Leqembi reverted to the cognitive decline rate of the placebo group during a gap period.
    • This underscores the necessity of continuous treatment even after initial plaque removal.

Implications for the Future

Leqembi’s long-term benefits highlight its potential as a critical treatment in managing Alzheimer’s disease. The study suggests that early intervention and sustained treatment are key to maximizing its benefits. The move towards more convenient administration methods could further enhance patient adherence and outcomes. As the prevalence of Alzheimer’s continues to rise, these findings offer hope for improved management of this challenging condition.

Alzheimer’s Amyloid Plaque Biogen Cognitive Decline Eisai Leqembi Long-term Study Maintenance Dose Regulatory Approval.
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
ayaksız
  • Website

Related Posts

Double Rainbows: Why the Outer Arc Reverses Its Colors

Kasım 18, 2026

Why Ice Floats—and Why Water Behaves Differently Near Freezing

Kasım 13, 2026

Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

Kasım 12, 2026
Add A Comment

Comments are closed.

Recent Posts
  • Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone
  • Cache-Control for Startups: No-Cache and No-Store Solve Different Problems
  • Tripod Center Columns: Extra Height Comes with a Stability Tradeoff
  • Double Rainbows: Why the Outer Arc Reverses Its Colors
  • Router Mode or Access Point Mode? Give Each Network Device a Clear Job
Tags
AI AI Chips AI Infrastructure Amazon Android Apple Artificial Intelligence Bitcoin ChatGPT China Cryptocurrency Cybersecurity data centers DeepSeek Donald Trump Electric Vehicles Elon Musk Ether Generative AI Google Huawei India Investment Iphone Meta Microsoft NASA National Security Nvidia OnePlus OpenAI Oppo Realme Samsung semiconductor industry Social media Sony SpaceX Technology Tesla Tether TikTok Vivo WhatsApp Xiaomi
Ayaksız
Instagram
© 2026 Ayaksız.

Type above and press Enter to search. Press Esc to cancel.